Download click - Massachusetts Society of Health

2017 MSHP Annual Meeting
Tuesday May 9, 2017 7:45 AM – 5:00 PM
Time
Topic/Speaker
7:00 – 8:00 AM
Registration
Attendees, Exhibitors, Posters
Welcome and Opening Remarks
Paul Arpino, PharmD – President, Massachusetts Society of Health System Pharmacists; Operations
Manager, Mount Auburn Hospital
Pharmacists Must be Leaders: Perspectives on Leveraging Leadership to Improve Patient Care
Keynote (1.0 CEU)
Paul Abramowitz, PharmD, ScD (Hon), FASHP – CEO, American Society of Health-System Pharmacists
USP 797 Implementation “The Ugly, the Bad, and the Good” (1.0 CEU-Law, sterile)
Marty Goldberg, RPh, MBA – Director of Pharmacy, Steward Good Samaritan Medical Center
Break/Exhibitors
A Game Plan to Surviving a Joint Commission Survey (1.0 CEU-Law)
May Adra, BS Pharm, PharmD, BCPS (BIDMC) – Pharmacy Clinical Coordinator, Medication Safety,
Beth Israel Deaconess Medical Center
Lunch/Exhibitors
Break (Room Set Up)
CLINICAL PROGRAMMING
LEADERSHIP PROGRAMMING
Yellow Card: FDA Warnings on Antibiotics* –
Team Huddle: Strategic Planning to Navigate the
Monica Mahoney, PharmD, BCPS AQ-ID
Future – Lindsay Smith, PharmD, MS (MGH)
(BIDMC)
Overcoming Acute Pain Management
Time Out for Opioid Law Update* – Karen Ryle, RPh,
Hurdles in the Tertiary Setting: The High Risk
MS (MGH)
Patient – Ewan McNicol, PharmD, MS (Tufts)
Lean in Pharmacy: Empowering Your Team to
Turning Heart Failure into Heart Success: a
Problem Solve* – Melissa Ortega, PharmD, MS
Review of Pharmacotherapeutic Approaches
(Tufts)/Neil Gilchrist, PharmD, MBA, BCPS (UMass)
to Heart Failure Management – Tara Lech,
PharmD, BCPS (Lahey)
7:45 – 8:00 AM
8:00 – 9:00 AM
9:00 – 10:00 AM
10:00 – 10:15 AM
10:15 – 11:15 AM
11:15 – 12:15 PM
12:15 – 12:30 PM
12:30 – 1:30 PM
1:30 – 2:30 PM
2:30 – 3:30 PM
3:30 – 3:45 PM
3:45 – 4:45 PM
Break - Awards/Recognitions Announced
These Aren’t Your Average Rookies: A Primer
on New and Emerging Insulins –Alissa Segal,
PharmD, CDE, CDTC, FCCP (MCPHS-U)
Hut, Hut, Hike! Breaking Even During Price Hikes in
the Intensive Care Unit* – William Vincent, PharmD,
BCCCP (BMC)
*Technician CE eligible
2017 MSHP Annual Meeting
Tuesday May 9, 2017 7:45 AM – 5:00 PM
Learning Objectives:
Speaker
Title
Paul
Abramowitz
Pharmacists Must be
Leaders: Perspectives on
Leveraging Leadership to
Improve Patient Care
Marty Goldberg
USP 797 Implementation
“The Ugly, the Bad, and the
Good”
May Adra
A Game Plan to Surviving a
Joint Commission Survey
Monica
Mahoney
Yellow Card: FDA Warnings
on Antibiotics
Lindsay Smith
Team Huddle: Strategic
Planning to Navigate the
Future
Ewan McNicol
Overcoming Acute Pain
Management Hurdles in the
3’ Setting – The High Risk
Patient
Objectives
At the end of this program, participants should be able to:
 Describe contemporary leadership perspectives
 Identify essential leadership knowledge, skills, and attributes
to advance practice
 Describe strategic leadership imperatives in the current
environment
 Illustrate examples of leadership excellence across the
pharmacy enterprise
 Review of key USP 797 sterile compounding Standards
 Discuss key Massachusetts regulations pertaining to USP 797
 Review of USP 797 Implementation considerations/issue
 Describe our “real life” experiences with USP 797 compliance
 Describe key components of a Joint Commission accreditation
visit
 Identify changes to medication management standards
 Develop a roadmap for preparing for The Joint Commission
visit
 Identify the role the FDA plays in updating drug warnings and
communication
 Evaluate the literature behind the recent FDA antimicrobial
drug interactions and adverse drug events
 Given a patient scenario, recommend a treatment plan to
manage and mitigate the FDA warnings
 Identify essential steps in the strategic planning process
 Review methods for facilitating a retreat and developing a
strategic plan
 Discuss effective implementation strategies and tools for
marketing success
 Outline principles for management of postoperative, trauma
and other types of acute pain
 Evaluate the evidence supporting, and the clinical application
of, multimodal analgesia
 With the help of a patient case, explain approaches to tailoring
regimens to individual patients, in particular those from high
risk populations
Karen Ryle
Time Out for Opioid Law
Update



Tara Lech
Turning Heart Failure into
Heart Success: A review of
pharmacotherapeutic
approaches to heart failure
management




Melissa Ortega
Neil Gilchrist
Alissa Segal
Lean in Pharmacy:
Empowering Your Team to
Problem Solve

These Aren’t Your Average
Rookies: A Primer on New
and Emerging Insulins





William Vincent
Hut, Hut, Hike! Breaking
Even During Price Hikes in
the Intensive Care Unit



Understand Chapter 52-Acts of 2016: “An act relative to
Substance Use Treatment, Education and Prevention as it
pertains to pharmacy”
Identify enhancements made to the states MassPAT
prescription monitoring program
Describe Massachusetts Board of Registration in pharmacy
requirement for developing procedures for validating
questionable prescriptions
Review various programs involving Naloxone dispensing
Review the pathophysiology of heart failure as it relates to
neurohormonal pathways
Identify pharmacotherapeutic treatment options for heart
failure (HF) and tailor use based upon individualized patient
characteristics
Adjust treatment plans for HF patients to improve morbidity
and mortality as well as reduce hospitalizations
List the common tools of Lean methodology used to evaluate
waste and improve efficiency
Define steps to create a Lean culture in your pharmacy team
Apply Lean concepts to problem-solving and how this can be
used in your pharmacy department
Evaluate how recently available insulin formulations (including
concentrated and follow-on biologic) may overcome
challenges of inpatient insulin needs
Distinguish the role of pharmacists in minimizing prescribing,
dispensing and insulin administration errors, particularly
during transitions in and out of inpatient settings
Discuss how to evaluate and integrate new and emerging
insulins into treatment plans in hospital settings and
transitions in care
Describe the current prescription medication price hike
epidemic
Discuss use of improvement science to break even during the
intravenous acetaminophen and sodium nitroprusside price
hikes
Identify lessons learned and proactive approaches to
overcome future drug pricing challenges